A citation-based method for searching scientific literature

Grzegorz S Nowakowski, Annalisa Chiappella, Thomas E Witzig, Michele Spina, Randy D Gascoyne, Lei Zhang, Jocelyne Flament, Jacqueline Repici, Umberto Vitolo. Future Oncol 2016
Times Cited: 67







List of co-cited articles
480 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.
A A Alizadeh, M B Eisen, R E Davis, C Ma, I S Lossos, A Rosenwald, J C Boldrick, H Sabet, T Tran, X Yu,[...]. Nature 2000
49

Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
Grzegorz S Nowakowski, Betsy LaPlant, William R Macon, Craig B Reeder, James M Foran, Garth D Nelson, Carrie A Thompson, Candido E Rivera, David J Inwards, Ivana N Micallef,[...]. J Clin Oncol 2015
276
44

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
Wyndham H Wilson, Ryan M Young, Roland Schmitz, Yandan Yang, Stefania Pittaluga, George Wright, Chih-Jian Lih, P Mickey Williams, Arthur L Shaffer, John Gerecitano,[...]. Nat Med 2015
731
43

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.
Christine P Hans, Dennis D Weisenburger, Timothy C Greiner, Randy D Gascoyne, Jan Delabie, German Ott, H Konrad Müller-Hermelink, Elias Campo, Rita M Braziel, Elaine S Jaffe,[...]. Blood 2004
41

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.
Andreas Rosenwald, George Wright, Wing C Chan, Joseph M Connors, Elias Campo, Richard I Fisher, Randy D Gascoyne, H Konrad Muller-Hermelink, Erlend B Smeland, Jena M Giltnane,[...]. N Engl J Med 2002
38

The 2016 revision of the World Health Organization classification of lymphoid neoplasms.
Steven H Swerdlow, Elias Campo, Stefano A Pileri, Nancy Lee Harris, Harald Stein, Reiner Siebert, Ranjana Advani, Michele Ghielmini, Gilles A Salles, Andrew D Zelenetz,[...]. Blood 2016
35

Stromal gene signatures in large-B-cell lymphomas.
G Lenz, G Wright, S S Dave, W Xiao, J Powell, H Zhao, W Xu, B Tan, N Goldschmidt, J Iqbal,[...]. N Engl J Med 2008
34

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
Anas Younes, Laurie H Sehn, Peter Johnson, Pier Luigi Zinzani, Xiaonan Hong, Jun Zhu, Caterina Patti, David Belada, Olga Samoilova, Cheolwon Suh,[...]. J Clin Oncol 2019
241
31

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Bertrand Coiffier, Eric Lepage, Josette Briere, Raoul Herbrecht, Hervé Tilly, Reda Bouabdallah, Pierre Morel, Eric Van Den Neste, Gilles Salles, Philippe Gaulard,[...]. N Engl J Med 2002
29

Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue.
David W Scott, George W Wright, P Mickey Williams, Chih-Jian Lih, William Walsh, Elaine S Jaffe, Andreas Rosenwald, Elias Campo, Wing C Chan, Joseph M Connors,[...]. Blood 2014
403
29

Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.
David W Scott, Anja Mottok, Daisuke Ennishi, George W Wright, Pedro Farinha, Susana Ben-Neriah, Robert Kridel, Garrett S Barry, Christoffer Hother, Pau Abrisqueta,[...]. J Clin Oncol 2015
249
28

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.
Roland Schmitz, George W Wright, Da Wei Huang, Calvin A Johnson, James D Phelan, James Q Wang, Sandrine Roulland, Monica Kasbekar, Ryan M Young, Arthur L Shaffer,[...]. N Engl J Med 2018
931
28

Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.
Umberto Vitolo, Marek Trněný, David Belada, John M Burke, Angelo Michele Carella, Neil Chua, Pau Abrisqueta, Judit Demeter, Ian Flinn, Xiaonan Hong,[...]. J Clin Oncol 2017
251
26

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Anas Younes, Catherine Thieblemont, Franck Morschhauser, Ian Flinn, Jonathan W Friedberg, Sandy Amorim, Benedicte Hivert, Jason Westin, Jessica Vermeulen, Nibedita Bandyopadhyay,[...]. Lancet Oncol 2014
210
25

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.
Bertrand Coiffier, Catherine Thieblemont, Eric Van Den Neste, Gérard Lepeu, Isabelle Plantier, Sylvie Castaigne, Sophie Lefort, Gérald Marit, Margaret Macro, Catherine Sebban,[...]. Blood 2010
959
23

Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.
Bjoern Chapuy, Chip Stewart, Andrew J Dunford, Jaegil Kim, Atanas Kamburov, Robert A Redd, Mike S Lawrence, Margaretha G M Roemer, Amy J Li, Marita Ziepert,[...]. Nat Med 2018
794
23

Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.
Francisco J Hernandez-Ilizaliturri, George Deeb, Pier L Zinzani, Stefano A Pileri, Farhana Malik, William R Macon, Andre Goy, Thomas E Witzig, Myron S Czuczman. Cancer 2011
235
22

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Nathalie A Johnson, Graham W Slack, Kerry J Savage, Joseph M Connors, Susana Ben-Neriah, Sanja Rogic, David W Scott, King L Tan, Christian Steidl, Laurie H Sehn,[...]. J Clin Oncol 2012
666
22


Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
R Eric Davis, Vu N Ngo, Georg Lenz, Pavel Tolar, Ryan M Young, Paul B Romesser, Holger Kohlhammer, Laurence Lamy, Hong Zhao, Yandan Yang,[...]. Nature 2010
20


Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.
Kieron Dunleavy, Stefania Pittaluga, Myron S Czuczman, Sandeep S Dave, George Wright, Nicole Grant, Margaret Shovlin, Elaine S Jaffe, John E Janik, Louis M Staudt,[...]. Blood 2009
394
20

Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
Catherine Thieblemont, Hervé Tilly, Maria Gomes da Silva, Rene-Olivier Casasnovas, Christophe Fruchart, Franck Morschhauser, Corinne Haioun, Julien Lazarovici, Anida Grosicka, Aurore Perrot,[...]. J Clin Oncol 2017
116
20

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
David Cunningham, Eliza A Hawkes, Andrew Jack, Wendi Qian, Paul Smith, Paul Mouncey, Christopher Pocock, Kirit M Ardeshna, John A Radford, Andrew McMillan,[...]. Lancet 2013
349
20

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
Michael Pfreundschuh, Lorenz Trümper, Anders Osterborg, Ruth Pettengell, Marek Trneny, Kevin Imrie, David Ma, Devinder Gill, Jan Walewski, Pier-Luigi Zinzani,[...]. Lancet Oncol 2006
19

A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.
William W L Choi, Dennis D Weisenburger, Timothy C Greiner, Miguel A Piris, Alison H Banham, Jan Delabie, Rita M Braziel, Huimin Geng, Javeed Iqbal, Georg Lenz,[...]. Clin Cancer Res 2009
474
19

Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.
Umberto Vitolo, Annalisa Chiappella, Silvia Franceschetti, Angelo Michele Carella, Ileana Baldi, Giorgio Inghirami, Michele Spina, Vincenzo Pavone, Marco Ladetto, Anna Marina Liberati,[...]. Lancet Oncol 2014
132
19

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Thomas M Habermann, Edie A Weller, Vicki A Morrison, Randy D Gascoyne, Peter A Cassileth, Jeffrey B Cohn, Shaker R Dakhil, Bruce Woda, Richard I Fisher, Bruce A Peterson,[...]. J Clin Oncol 2006
17

Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Tina Marie Green, Ken H Young, Carlo Visco, Zijun Y Xu-Monette, Attilio Orazi, Ronald S Go, Ole Nielsen, Ole V Gadeberg, Torben Mourits-Andersen, Mikael Frederiksen,[...]. J Clin Oncol 2012
486
17

Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
H Tilly, M Gomes da Silva, U Vitolo, A Jack, M Meignan, A Lopez-Guillermo, J Walewski, M André, P W Johnson, M Pfreundschuh,[...]. Ann Oncol 2015
451
17

Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab.
Paul N Meyer, Kai Fu, Timothy C Greiner, Lynette M Smith, Jan Delabie, Randy D Gascoyne, German Ott, Andreas Rosenwald, Rita M Braziel, Elias Campo,[...]. J Clin Oncol 2011
348
17

Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.
Anupama Reddy, Jenny Zhang, Nicholas S Davis, Andrea B Moffitt, Cassandra L Love, Alexander Waldrop, Sirpa Leppa, Annika Pasanen, Leo Meriranta, Marja-Liisa Karjalainen-Lindsberg,[...]. Cell 2017
579
17

Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma.
Michael Crump, Sirpa Leppä, Luis Fayad, Je Jung Lee, Alice Di Rocco, Michinori Ogura, Hans Hagberg, Frederick Schnell, Robert Rifkin, Andreas Mackensen,[...]. J Clin Oncol 2016
86
16

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).
Michael Pfreundschuh, Joerg Schubert, Marita Ziepert, Rudolf Schmits, Martin Mohren, Eva Lengfelder, Marcel Reiser, Christina Nickenig, Michael Clemens, Norma Peter,[...]. Lancet Oncol 2008
793
16

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.
Georg Lenz, George W Wright, N C Tolga Emre, Holger Kohlhammer, Sandeep S Dave, R Eric Davis, Shannon Carty, Lloyd T Lam, A L Shaffer, Wenming Xiao,[...]. Proc Natl Acad Sci U S A 2008
702
16

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.
Michael Crump, Sattva S Neelapu, Umar Farooq, Eric Van Den Neste, John Kuruvilla, Jason Westin, Brian K Link, Annette Hay, James R Cerhan, Liting Zhu,[...]. Blood 2017
759
16

Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Annette M Staiger, Marita Ziepert, Heike Horn, David W Scott, Thomas F E Barth, Heinz-Wolfram Bernd, Alfred C Feller, Wolfram Klapper, Monika Szczepanowski, Michael Hummel,[...]. J Clin Oncol 2017
143
16

Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
John P Leonard, Kathryn S Kolibaba, James A Reeves, Anil Tulpule, Ian W Flinn, Tatjana Kolevska, Robert Robles, Christopher R Flowers, Robert Collins, Nicholas J DiBella,[...]. J Clin Oncol 2017
106
16

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
Sattva S Neelapu, Frederick L Locke, Nancy L Bartlett, Lazaros J Lekakis, David B Miklos, Caron A Jacobson, Ira Braunschweig, Olalekan O Oluwole, Tanya Siddiqi, Yi Lin,[...]. N Engl J Med 2017
16

Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.
Fritz Offner, Olga Samoilova, Evgenii Osmanov, Hyeon-Seok Eom, Max S Topp, João Raposo, Viacheslav Pavlov, Deborah Ricci, Shalini Chaturvedi, Eugene Zhu,[...]. Blood 2015
91
14

Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
Gonzalo Gutiérrez-García, Teresa Cardesa-Salzmann, Fina Climent, Eva González-Barca, Santiago Mercadal, José L Mate, Juan M Sancho, Leonor Arenillas, Sergi Serrano, Lourdes Escoda,[...]. Blood 2011
237
14

Oncogenically active MYD88 mutations in human lymphoma.
Vu N Ngo, Ryan M Young, Roland Schmitz, Sameer Jhavar, Wenming Xiao, Kian-Huat Lim, Holger Kohlhammer, Weihong Xu, Yandan Yang, Hong Zhao,[...]. Nature 2011
13

Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.
Jia Ruan, Peter Martin, Richard R Furman, Shing M Lee, Ken Cheung, Julie M Vose, Ann Lacasce, Julia Morrison, Rebecca Elstrom, Scott Ely,[...]. J Clin Oncol 2011
244
13

Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.
Matthew J Maurer, Hervé Ghesquières, Jean-Philippe Jais, Thomas E Witzig, Corinne Haioun, Carrie A Thompson, Richard Delarue, Ivana N Micallef, Frédéric Peyrade, William R Macon,[...]. J Clin Oncol 2014
241
13

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Christian Gisselbrecht, Bertram Glass, Nicolas Mounier, Devinder Singh Gill, David C Linch, Marek Trneny, Andre Bosly, Nicolas Ketterer, Ofer Shpilberg, Hans Hagberg,[...]. J Clin Oncol 2010
13

Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.
Ryan D Morin, Maria Mendez-Lago, Andrew J Mungall, Rodrigo Goya, Karen L Mungall, Richard D Corbett, Nathalie A Johnson, Tesa M Severson, Readman Chiu, Matthew Field,[...]. Nature 2011
13

Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.
Nancy L Bartlett, Wyndham H Wilson, Sin-Ho Jung, Eric D Hsi, Matthew J Maurer, Levi D Pederson, Mei-Yin C Polley, Brandelyn N Pitcher, Bruce D Cheson, Brad S Kahl,[...]. J Clin Oncol 2019
185
13

Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.
Andrew Davies, Thomas E Cummin, Sharon Barrans, Tom Maishman, Christoph Mamot, Urban Novak, Josh Caddy, Louise Stanton, Shamim Kazmi-Stokes, Andrew McMillan,[...]. Lancet Oncol 2019
118
13

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.
Alexander M Lesokhin, Stephen M Ansell, Philippe Armand, Emma C Scott, Ahmad Halwani, Martin Gutierrez, Michael M Millenson, Adam D Cohen, Stephen J Schuster, Daniel Lebovic,[...]. J Clin Oncol 2016
698
11

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.
Adam M Petrich, Mitul Gandhi, Borko Jovanovic, Jorge J Castillo, Saurabh Rajguru, David T Yang, Khushboo A Shah, Jeremy D Whyman, Frederick Lansigan, Francisco J Hernandez-Ilizaliturri,[...]. Blood 2014
305
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.